PriceTargets.com logo

argenx - ARGX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $550.44
  • Forecasted Upside: 0.23%
  • Number of Analysts: 22
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 17 Buy Ratings
  • 1 Strong Buy Ratings
$549.19 As of 10/30/2024 03:52 PM ET
▼ -3.69 (-0.67%)

This chart shows the closing price for ARGX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New argenx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARGX

Analyst Price Target is $550.44
▲ +0.23% Upside Potential
This price target is based on 22 analysts offering 12 month price targets for argenx in the last 3 months. The average price target is $550.44, with a high forecast of $641.00 and a low forecast of $408.00. The average price target represents a 0.23% upside from the last price of $549.19.

This chart shows the closing price for ARGX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 22 polled investment analysts is to moderate buy stock in argenx. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 1 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 1 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 1 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 1 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 1 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 1 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 1 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 1 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/17/2024CitigroupBoost TargetBuy ➝ Buy$512.00 ➝ $635.00
10/10/2024Raymond JamesReiterated RatingStrong-Buy$605.00
10/4/2024Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
9/26/2024GuggenheimReiterated RatingBuy ➝ Buy$585.00 ➝ $585.00
8/23/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$500.00 ➝ $640.00
8/6/2024BarclaysUpgradeEqual Weight ➝ Overweight
7/29/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$490.00 ➝ $515.00
7/26/2024GuggenheimBoost TargetBuy ➝ Buy$545.00 ➝ $585.00
7/26/2024WedbushBoost TargetOutperform ➝ Outperform$519.00 ➝ $560.00
7/26/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$543.00 ➝ $547.00
7/26/2024HC WainwrightBoost TargetBuy ➝ Buy$504.00 ➝ $533.00
7/25/2024Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
7/23/2024OppenheimerUpgradeMarket Perform ➝ Outperform$546.00 ➝ $546.00
7/22/2024Truist FinancialBoost TargetBuy ➝ Buy$480.00 ➝ $540.00
7/17/2024HC WainwrightBoost TargetBuy ➝ Buy$490.00 ➝ $504.00
7/17/2024WedbushReiterated RatingOutperform ➝ Outperform$519.00 ➝ $519.00
7/12/2024Evercore ISIBoost TargetOutperform ➝ Outperform$478.00 ➝ $533.00
6/26/2024WedbushReiterated RatingOutperform ➝ Outperform$519.00 ➝ $519.00
6/25/2024Truist FinancialBoost TargetBuy ➝ Buy$440.00 ➝ $480.00
6/24/2024Bank of AmericaReiterated RatingBuy ➝ Buy$535.00 ➝ $607.00
6/24/2024Stifel NicolausBoost TargetBuy ➝ Buy$485.00 ➝ $500.00
6/24/2024Piper SandlerBoost TargetOverweight ➝ Overweight$522.00 ➝ $535.00
6/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$448.00 ➝ $448.00
6/24/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$478.00 ➝ $542.00
6/17/2024William BlairReiterated RatingMarket Perform
6/17/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$522.00 ➝ $522.00
6/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$448.00 ➝ $448.00
5/28/2024Morgan StanleyLower TargetOverweight ➝ Overweight$515.00 ➝ $510.00
5/13/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$560.00 ➝ $500.00
5/10/2024HC WainwrightLower TargetBuy ➝ Buy$451.00 ➝ $448.00
5/10/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$471.00 ➝ $468.00
4/18/2024WedbushReiterated RatingOutperform ➝ Outperform$521.00
4/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$451.00
3/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$451.00
3/26/2024ScotiabankBoost TargetSector Perform ➝ Sector Perform$402.00 ➝ $408.00
3/22/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$471.00
3/5/2024Truist FinancialBoost TargetBuy ➝ Buy$370.00 ➝ $440.00
3/1/2024ScotiabankBoost TargetSector Perform ➝ Sector Perform$346.00 ➝ $402.00
3/1/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$462.00 ➝ $471.00
3/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$451.00
3/1/2024Robert W. BairdLower TargetOutperform ➝ Outperform$505.00 ➝ $490.00
2/20/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$472.00 ➝ $478.00
2/15/2024Wolfe ResearchInitiated CoveragePeer Perform
1/26/2024Piper SandlerBoost TargetOverweight ➝ Overweight$518.00 ➝ $522.00
1/18/2024Piper SandlerBoost TargetOverweight ➝ Overweight$515.00 ➝ $518.00
12/21/2023ScotiabankLower TargetSector Perform ➝ Sector Perform$444.00 ➝ $346.00
12/21/2023Evercore ISILower TargetOutperform ➝ Outperform$594.00 ➝ $436.00
12/21/2023Piper SandlerLower TargetOverweight ➝ Overweight$575.00 ➝ $515.00
12/21/2023HC WainwrightLower TargetBuy ➝ Buy$582.00 ➝ $451.00
12/21/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$585.00 ➝ $470.00
12/21/2023Raymond JamesLower TargetStrong-Buy ➝ Strong-Buy$580.00 ➝ $520.00
12/20/2023William BlairDowngradeOutperform ➝ Market Perform
12/20/2023Truist FinancialReiterated RatingBuy ➝ Buy$550.00
12/20/2023Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
12/18/2023Stifel NicolausBoost TargetBuy ➝ Buy$557.00 ➝ $560.00
12/12/2023TD CowenBoost TargetOutperform ➝ Outperform$612.00 ➝ $641.00
12/5/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$615.00 ➝ $560.00
11/30/2023Morgan StanleyLower TargetOverweight ➝ Overweight$607.00 ➝ $586.00
11/29/2023Truist FinancialLower TargetBuy ➝ Buy$570.00 ➝ $550.00
11/29/2023Raymond JamesLower TargetStrong-Buy ➝ Strong-Buy$600.00 ➝ $580.00
11/29/2023HC WainwrightLower TargetBuy ➝ Buy$595.00 ➝ $582.00
11/29/2023CitigroupLower TargetBuy ➝ Buy$610.00 ➝ $591.00
11/1/2023Truist FinancialReiterated RatingBuy ➝ Buy$570.00
11/1/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$604.00 ➝ $607.00
10/2/2023Jefferies Financial GroupBoost Target$605.00 ➝ $628.00
10/2/2023Truist FinancialReiterated RatingBuy ➝ Buy$570.00
9/18/2023HC WainwrightReiterated RatingBuy ➝ Buy$595.00
8/31/2023Piper SandlerBoost TargetOverweight ➝ Overweight$595.00 ➝ $600.00
7/31/2023ScotiabankInitiated CoverageSector Perform$516.00
7/28/2023GuggenheimBoost TargetBuy$545.00 ➝ $590.00
7/28/2023Wells Fargo & CompanyBoost TargetOverweight$606.00 ➝ $609.00
7/28/2023HC WainwrightReiterated RatingBuy ➝ Buy$595.00
7/24/2023Piper SandlerBoost TargetOverweight$545.00 ➝ $575.00
7/24/2023UBS GroupDowngradeBuy ➝ Neutral$480.00 ➝ $570.00
7/21/2023HC WainwrightBoost TargetBuy$494.00 ➝ $595.00
7/20/2023Morgan StanleyBoost TargetOverweight$452.00 ➝ $602.00
7/18/2023WedbushReiterated RatingOutperform ➝ Outperform$570.00
7/18/2023Bank of AmericaBoost Target$446.00 ➝ $572.00
7/18/2023Robert W. BairdBoost Target$460.00 ➝ $566.00
7/18/2023Wells Fargo & CompanyBoost Target$544.00 ➝ $606.00
7/18/2023GuggenheimBoost Target$505.00 ➝ $545.00
7/18/2023CitigroupBoost Target$450.00 ➝ $592.00
7/17/2023Stifel NicolausBoost Target$478.00 ➝ $601.00
7/17/2023Jefferies Financial GroupBoost Target$497.00 ➝ $513.00
7/17/2023Evercore ISIInitiated CoverageOutperform$436.00
6/21/2023Jefferies Financial GroupBoost Target$455.00 ➝ $465.00
6/15/2023Societe GeneraleInitiated CoverageSell
5/31/2023UBS GroupInitiated CoverageBuy$480.00
5/5/2023888Reiterated RatingMaintains
5/5/2023Bank of AmericaBoost Target$444.00 ➝ $446.00
5/5/2023JMP SecuritiesLower Target$448.00 ➝ $445.00
5/5/2023Truist FinancialBoost Target$420.00 ➝ $440.00
5/5/2023HC WainwrightBoost Target$182.00 ➝ $494.00
4/25/2023CitigroupInitiated CoverageBuy$450.00
4/21/2023WedbushReiterated RatingOutperform$432.00
3/20/2023HC WainwrightBoost Target$480.00 ➝ $482.00
3/14/2023Robert W. BairdUpgradeNeutral ➝ Outperform$460.00
3/3/2023Leerink PartnersBoost TargetOutperform$430.00 ➝ $435.00
3/3/2023JMP SecuritiesBoost TargetMarket Outperform$443.00 ➝ $448.00
3/3/2023SVB SecuritiesBoost Target$430.00 ➝ $435.00
3/3/2023HC WainwrightReiterated RatingBuy$480.00
2/23/2023Piper SandlerBoost TargetOverweight$465.00 ➝ $475.00
1/25/2023CowenBoost TargetOutperform$441.00 ➝ $458.00
1/10/2023HC WainwrightBoost TargetBuy$440.00 ➝ $480.00
12/22/2022Stifel NicolausBoost TargetBuy$471.00 ➝ $478.00
12/6/2022William BlairInitiated CoverageOutperform
12/6/2022BarclaysBoost TargetOverweight ➝ Overweight€405.00 ➝ €450.00
11/14/2022JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight€470.00 ➝ €480.00
10/28/2022Morgan StanleyBoost TargetOverweight$401.00 ➝ $450.00
10/28/2022Truist FinancialBoost TargetBuy$410.00 ➝ $420.00
10/28/2022HC WainwrightBoost TargetBuy$425.00 ➝ $440.00
10/28/2022Leerink PartnersBoost TargetOutperform$428.00 ➝ $430.00
10/21/2022Evercore ISIUpgradeOutperform
10/18/2022Wells Fargo & CompanyBoost TargetOverweight$461.00 ➝ $469.00
10/11/2022OppenheimerInitiated CoverageMarket Perform
9/22/2022Deutsche Bank AktiengesellschaftBoost TargetBuy ➝ Buy€400.00 ➝ €425.00
9/22/2022JMP SecuritiesReiterated RatingBuy$427.00
8/26/2022Piper SandlerBoost TargetOverweight$450.00 ➝ $465.00
7/29/2022HC WainwrightBoost TargetBuy$400.00 ➝ $425.00
7/29/2022Leerink PartnersBoost TargetOutperform$404.00 ➝ $428.00
7/29/2022Robert W. BairdReiterated RatingDowngrade
7/29/2022Morgan StanleyBoost TargetOverweight$375.00 ➝ $401.00
7/28/2022Robert W. BairdDowngradeOutperform ➝ Neutral$374.00 ➝ $460.00
7/28/2022Stifel NicolausBoost Target$460.00 ➝ $471.00
7/25/2022Piper SandlerBoost TargetOverweight$415.00 ➝ $425.00
7/14/2022JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight€390.00 ➝ €430.00
6/27/2022Stifel NicolausInitiated CoverageBuy$460.00
5/27/2022Piper SandlerBoost TargetOverweight$375.00 ➝ $415.00
5/24/2022Leerink PartnersReiterated RatingOutperform
5/13/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
5/6/2022JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight€350.00 ➝ €370.00
5/3/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$375.00
3/7/2022Morgan StanleyBoost TargetEqual Weight$274.00 ➝ $278.00
3/4/2022HC WainwrightReiterated RatingBuy$400.00
2/1/2022Morgan StanleyLower TargetEqual Weight$339.00 ➝ $274.00
1/18/2022Morgan StanleyLower TargetEqual Weight$351.00 ➝ $339.00
1/4/2022JPMorgan Chase & Co.Boost Target€340.00 ➝ €350.00
12/21/2021Truist FinancialBoost TargetBuy ➝ Buy$350.00 ➝ $365.00
12/21/2021JMP SecuritiesBoost TargetMarket Outperform$368.00 ➝ $418.00
12/20/2021Wells Fargo & CompanyBoost TargetOverweight$390.00 ➝ $395.00
12/20/2021Credit Suisse GroupBoost TargetNeutral$297.00 ➝ $340.00
12/20/2021Raymond JamesBoost TargetStrong-Buy$390.00 ➝ $455.00
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$390.00
12/2/2021Kepler Capital MarketsUpgradeHold ➝ Buy$220.00 ➝ $290.00
11/29/2021Piper SandlerUpgradeNeutral ➝ Overweight$250.00 ➝ $354.00
10/28/2021GuggenheimUpgradeNeutral ➝ Buy$330.00
10/28/2021Raymond JamesUpgradeOutperform ➝ Strong-Buy$390.00
10/19/2021BarclaysUpgradeEqual Weight ➝ Overweight
10/6/2021Jefferies Financial GroupInitiated CoverageBuy$362.00
10/4/2021Robert W. BairdBoost TargetOutperform$333.00 ➝ $355.00
9/23/2021Redburn PartnersUpgradeNeutral ➝ Buy$205.00 ➝ $325.00
9/7/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$332.00 ➝ $351.00
9/2/2021BarclaysReiterated RatingEqual Weight
8/4/2021JPMorgan Chase & Co.Reiterated RatingOverweight
8/3/2021Morgan StanleyBoost TargetOverweight$324.00 ➝ $332.00
7/23/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold$250.00
7/22/2021WedbushBoost TargetOutperform$344.00 ➝ $362.00
7/21/2021HC WainwrightReiterated RatingBuy$400.00
6/18/2021UBS GroupInitiated CoverageBuy$390.00
6/8/2021WedbushLower TargetPositive ➝ Outperform$356.00 ➝ $344.00
6/7/2021Piper SandlerLower TargetNeutral$309.00 ➝ $250.00
5/18/2021Morgan StanleyBoost TargetOverweight$321.00 ➝ $324.00
5/16/2021Kepler Capital MarketsDowngradeHold
5/10/2021HC WainwrightUpgradeNeutral ➝ Buy$320.00 ➝ $400.00
4/23/2021Redburn PartnersInitiated CoverageNeutral
4/19/2021Morgan StanleyLower TargetOverweight$326.00 ➝ $321.00
3/8/2021Morgan StanleyBoost TargetOverweight$311.00 ➝ $326.00
3/5/2021Kepler Capital MarketsReiterated RatingHold
3/5/2021HC WainwrightBoost TargetNeutral$265.00 ➝ $320.00
2/18/2021CowenBoost TargetOutperform$317.00 ➝ $430.00
2/10/2021BarclaysReiterated RatingEqual Weight
2/4/2021Piper SandlerBoost Target$303.00 ➝ $309.00
2/2/2021Wells Fargo & CompanyBoost TargetEqual Weight$272.00 ➝ $326.00
2/1/2021Piper SandlerDowngradeOverweight ➝ Neutral$300.00 ➝ $303.00
2/1/2021JMP SecuritiesReiterated RatingPositive ➝ Outperform$307.00 ➝ $421.00
1/7/2021Wells Fargo & CompanyBoost TargetEqual Weight$249.00 ➝ $272.00
1/7/2021JMP SecuritiesBoost TargetOutperform$271.00 ➝ $307.00
1/4/2021GuggenheimDowngradeBuy ➝ Neutral
12/16/2020Morgan StanleyBoost TargetOverweight$295.00 ➝ $311.00
12/15/2020Truist FinancialBoost Target$275.00 ➝ $350.00
11/11/2020Morgan StanleyBoost TargetOverweight$281.00 ➝ $295.00
10/29/2020JPMorgan Chase & Co.Reiterated RatingOverweight
10/23/2020BarclaysReiterated RatingEqual Weight
10/23/2020HC WainwrightLower TargetNeutral$272.00 ➝ $265.00
10/13/2020BarclaysReiterated RatingEqual Weight
10/6/2020Bank of AmericaBoost TargetBuy$265.00 ➝ $298.00
10/6/2020Robert W. BairdBoost TargetPositive ➝ Outperform$265.00 ➝ $275.00
10/5/2020JMP SecuritiesBoost TargetOutperform$245.00 ➝ $271.00
9/30/2020Piper SandlerBoost TargetPositive ➝ Overweight$258.00 ➝ $300.00
8/24/2020Raymond JamesInitiated CoverageOutperform$257.00
8/10/2020Morgan StanleyBoost TargetOverweight$258.00 ➝ $281.00
7/31/2020Kepler Capital MarketsDowngradeBuy ➝ Hold
7/30/2020Stifel NicolausReiterated RatingBuy$253.00
7/29/2020HC WainwrightInitiated CoverageNeutral$272.00
6/17/2020CowenReiterated RatingBuy
5/29/2020JPMorgan Chase & Co.Boost TargetOverweight$179.00 ➝ $246.00
5/27/2020Morgan StanleyBoost TargetOverweight$180.00 ➝ $258.00
5/27/2020GuggenheimReiterated RatingBuy$201.00 ➝ $225.00
5/27/2020Robert W. BairdBoost TargetPositive ➝ Outperform$170.00 ➝ $235.00
5/27/2020SunTrust BanksBoost TargetBuy$192.00 ➝ $240.00
5/26/2020JMP SecuritiesBoost TargetOutperform$170.00 ➝ $237.00
5/26/2020Piper SandlerBoost Target$198.00 ➝ $258.00
5/26/2020Stifel NicolausBoost TargetPositive ➝ Buy$163.00 ➝ $253.00
5/21/2020Credit Suisse GroupBoost TargetNeutral$150.00 ➝ $160.00
5/17/2020NomuraReiterated RatingBuy$255.00
5/14/2020Stifel NicolausReiterated RatingBuy$163.00
3/4/2020Nomura SecuritiesReiterated RatingBuy$255.00
2/24/2020GuggenheimBoost TargetBuy$164.00 ➝ $201.00
2/10/2020Bank of AmericaInitiated CoverageBuy$181.00
1/17/2020WedbushReiterated RatingOutperform$184.00 ➝ $184.00
1/17/2020Morgan StanleyBoost TargetOverweight$170.00 ➝ $180.00
1/9/2020WedbushBoost TargetPositive ➝ Outperform$179.00 ➝ $184.00
1/9/2020JMP SecuritiesReiterated RatingOutperform$164.00 ➝ $170.00
1/9/2020Stifel NicolausReiterated RatingBuy ➝ Average
1/6/2020Piper Sandler CompaniesBoost TargetOverweight$177.00 ➝ $194.00
12/16/2019SunTrust BanksBoost TargetBuy$160.00 ➝ $192.00
12/8/2019Stifel NicolausBoost TargetBuy$154.00 ➝ $170.00
11/18/2019SunTrust BanksBoost TargetBuy$150.00 ➝ $160.00
11/8/2019Piper Sandler CompaniesReiterated RatingOverweight
11/5/2019Credit Suisse GroupInitiated CoverageNeutral$137.00 ➝ $137.00
10/31/2019William BlairUpgradeMarket Perform ➝ Outperform
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.92 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 20 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 10 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 21 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
6/2/2024
  • 20 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 19 very positive mentions
  • 23 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/1/2024
  • 7 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 19 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 14 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 14 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

argenx logo
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Read More

Today's Range

Now: $549.19
Low: $547.27
High: $555.91

50 Day Range

MA: $536.03
Low: $514.23
High: $568.49

52 Week Range

Now: $549.19
Low: $327.73
High: $571.97

Volume

139,093 shs

Average Volume

305,630 shs

Market Capitalization

$32.64 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Frequently Asked Questions

What sell-side analysts currently cover shares of argenx?

The following equities research analysts have issued stock ratings on argenx in the last twelve months: Bank of America Co., Barclays PLC, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Evercore ISI, Guggenheim, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Robert W. Baird, Scotiabank, Stifel Nicolaus, TD Cowen, Truist Financial Co., Wedbush, Wells Fargo & Company, William Blair, and Wolfe Research.
View the latest analyst ratings for ARGX.

What is the current price target for argenx?

18 Wall Street analysts have set twelve-month price targets for argenx in the last year. Their average twelve-month price target is $550.44, suggesting a possible upside of 0.2%. TD Cowen has the highest price target set, predicting ARGX will reach $641.00 in the next twelve months. Scotiabank has the lowest price target set, forecasting a price of $408.00 for argenx in the next year.
View the latest price targets for ARGX.

What is the current consensus analyst rating for argenx?

argenx currently has 4 hold ratings, 17 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ARGX.

What other companies compete with argenx?

Other companies that are similar to argenx include Gilead Sciences, BioNTech, Biogen, Moderna and Vaxcyte. Learn More about companies similar to argenx.

How do I contact argenx's investor relations team?

argenx's physical mailing address is Willemstraat 5, Breda P7, 4811 AH. The company's listed phone number is (176) 303-0488 and its investor relations email address is [email protected]. The official website for argenx is www.argenx.com. Learn More about contacing argenx investor relations.